Literature DB >> 22265712

Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies.

M Mahler1, A Radice, W Yang, C Bentow, A Seaman, L Bianchi, R A Sinico.   

Abstract

BACKGROUND: The detection of anti-proteinase 3 (PR3) and anti-myeloperoxidase (MPO) autoantibodies represents a serological hallmark in the diagnosis of small vessel vasculitis such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). We evaluated novel chemiluminescence assays (CIAs) for PR3- and MPO-ANCA detection and investigated their utility for disease activity monitoring.
METHODS: Sera collected from GPA (n=41) and MPA (n=30) patients were tested by QUANTA Lite® PR-3 and MPO ELISAs (INOVA Diagnostics) and by the QUANTA Flash™ PR3 and MPO CIAs (INOVA). Precision and linearity were analyzed following reference guidelines. The recently launched reference sera for PR3-and MPO-ANCA (Centers of Disease Control and prevention, CDC) were used to establish international units for the new assays. Disease activity was determined using the Birmingham Vasculitis Activity Score.
RESULTS: The international standards for PR3-and MPO-ANCA yielded results of 403 CU and 332 CU in the novel CIAs, respectively. The linearity analysis showed linear regression values>0.97 with slopes between 0.96 and 1.04. Total variation obtained from the precision study showed CV% of ≤7.4 for PR3-ANCA and ≤12.8 for MPO-ANCA. Good agreement (Spearman rho ≥ 0.89) was observed between CIA and ELISA. PR3-ANCA determined by CIA, but not by ELISA, was correlated with disease activity. No correlation was found for MPO-ANCA.
CONCLUSION: The novel PR3- and MPO-ANCA CIAs show good precision, linearity and correlation to ELISA. In addition, PR3-ANCA by CIA show correlation with disease activity. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265712     DOI: 10.1016/j.cca.2012.01.004

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  25 in total

Review 1.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests.

Authors:  Maria Infantino; M Manfredi; M Merone; V Grossi; M Benucci; F Li Gobbi; F Bandinelli; A Damiani; P Soda
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

3.  Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus.

Authors:  Chelsea Bentow; Gabriella Lakos; Rachel Rosenblum; Cassandra Bryant; Andrea Seaman; Michael Mahler
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

4.  Discrepancies between two immunoassays for the determination of MPO and PR3 autoantibodies.

Authors:  Qian Sun; Boris Calderon; Zhen Zhao
Journal:  Clin Chim Acta       Date:  2017-05-08       Impact factor: 3.786

5.  Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease.

Authors:  Maria Teresa Arias-Loste; Geovana Bonilla; Irene Moraleja; Michael Mahler; Miguel Angel Mieses; Beatriz Castro; Montserrat Rivero; Javier Crespo; Marcos López-Hoyos
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

Review 6.  New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies.

Authors:  Cecilia Beatrice Chighizola; Maria Gerosa; Pier Luigi Meroni
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 7.  [Paradigm shift in ANCA diagnostics : New international consensus recommendations].

Authors:  E Csernok; N Kempiners; B Hellmich
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

8.  Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort.

Authors:  Makoto Miyara; Roger Albesa; Jean-Luc Charuel; Mohamed El Amri; Marvin J Fritzler; Pascale Ghillani-Dalbin; Zahir Amoura; Lucile Musset; Michael Mahler
Journal:  Clin Dev Immunol       Date:  2013-02-07

9.  Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay.

Authors:  Michael Mahler; Cristina Gascon; Sima Patel; Angela Ceribelli; Marvin J Fritzler; Andreas Swart; Edward K L Chan; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2013-04-12       Impact factor: 5.156

10.  Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome.

Authors:  Shulan Zhang; Ziyan Wu; Ping Li; Yina Bai; Fengchun Zhang; Yongzhe Li
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.